As of April 2021, four adenovirus vector vaccines for COVID-19 have been authorized in at least one country:
- The Oxford–AstraZeneca vaccine uses the modified chimpanzee adenovirus ChAdOx1
- Sputnik V uses human adenovirus serotype 26 for the first shot and serotype 5 for the second.
- The Johnson & Johnson vaccine uses serotype 26.
- Convidecia uses serotype 5.
Research article excerpt:
During the last months many countries have started the immunization of millions of people by using vector-based vaccines. Unfortunately, severe side effects became overt during these vaccination campaigns: cerebral venous sinus thromboses (CVST), absolutely rare under normal life conditions, were found as a severe side effect that occured 4-14 days after first vaccinations.
The research is saying that these vaccines can cause blood clots 4 to 14 days after vaccination.
Sources:
- May 26, 2021. Eric Kowarz, Lea Krutzke, Jenny Reis, Silvia Bracharz, Stefan Kochanek, and Rolf Marschalek. “‘Vaccine-Induced Covid-19 Mimicry’ Syndrome:Splice Reactions within the SARS-CoV-2 Spike Open Reading Frame Result in Spike Protein Variants That May Cause Thromboembolic Events in Patients Immunized with Vector-Based Vaccines.”
https://doi.org/10.21203/rs.3.rs-558954/v1.
Research Journal. - April 13, 2021. “Understanding Viral Vector COVID-19 Vaccines.” Centers for Disease Control and Prevention.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.html.
Centers for Disease Control and Prevention. - “Viral Vector Vaccine.” In Wikipedia.
https://en.wikipedia.org/w/index.php?title=Viral_vector_vaccine.
Reference.